ARMR Sciences Generates Anti-Fentanyl Immune Response in Clinical Trial

NORTH PALM BEACH, Fla., Sept. 03, 2026 /CourierPR/ -- SRX Global Inc., an AI-driven investment platform focused on generating long-term shareholder value through strategic assets and high-conviction operating companies, has provided an update on its portfolio company, ARMR Sciences, a clinical-stage biodefense company. The update, delivered by ARMR's CEO, Collin Gage, highlights significant progress in ARMR's lead product, ARMR-100, which aims to protect against synthetic drugs, including fentanyl.

ARMR recently announced that its Phase 1/2 clinical trial of ARMR-100 has generated an anti-fentanyl immune response in humans, with favorable safety data. According to CEO Kent Cunningham of SRX Global Inc., "This is a very encouraging period for ARMR. As an early stage investment for SRX, ARMR is demonstrating strong biological validation and strategic momentum, reinforcing our investment thesis."

In addition to the clinical trial success, ARMR has received a Department of War (DoW) contract to partner on developing a generative AI platform for medical countermeasures. This contract, designed to support FDA Animal Rule compliance, aims to accelerate and improve the development of medical countermeasures against synthetic drugs. Cunningham emphasized, "This contract underscores the strategic importance of ARMR's work and provides a practical pathway to advance our technology in priority defense applications."

ARMR has also engaged with the FDA, receiving acceptance into the Model-Informed Drug Development (MIDD) program. This program allows ARMR to collaborate directly with FDA staff to discuss the application of computational modeling in its development strategy. Cunningham stated, "The combination of our DoW contract and MIDD acceptance represents a significant strategic and regulatory milestone for ARMR."

The company's Chief Medical Officer, Dr. Seth Toback, provided further details on the clinical trial progress. He noted, "Following the second vaccine dose, we observed a significant increase in anti-fentanyl IgG titers, supporting continued dose escalation and progression of the study. Our first fentanyl challenge cohort is underway, and we are cautiously optimistic about the potential of ARMR-100."

Collin Gage added, "These developments are critical steps in our journey to protect against synthetic drug threats. We are grateful for the continued support of our partners and look forward to sharing further updates as we advance our mission."

ARMR Sciences, a clinical-stage biodefense company, is developing a platform of medical countermeasures against synthetic drugs, including fentanyl, and other emerging chemical threats. Its lead product, ARMR-100, is designed to generate a protective immune response, producing antibodies that can bind and neutralize synthetic molecules.

SRX Global Inc. remains committed to generating long-term shareholder value through its investments in high-conviction operating companies and strategic assets. The company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.